Show results for
Refine by
Antibody Therapeutics Suppliers Serving Iran
24 companies found
based inRedcar, UNITED KINGDOM
Absolute Antibody was founded in 2012 with a vision to make engineered recombinant antibodies accessible to all, and we remain the only company 100% focused on recombinant antibody technology. Though recombinant antibodies are standard in the ...
Polyclonal antibodies are widely used reagents across research and diagnostics. They are generated by immunizing animals with an immunogen and harvesting the animals’ blood to obtain immunoreactive serum. While polyclonal antibodies offer a ...
based inMumbai, INDIA
Krishgen BioSystems (Krishgen) is privately-owned biotech firm with academic linkages to provide tools to scientists. With the strong background in immunology, we believe in the delivering quality kits, reagents and consumables. Certified and ...
Adalimumab biosimilar is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor (TNF), was created using phage display technology resulting in an antibody with human derived heavy and light chain variable regions and ...
based inDuisburg, GERMANY
Genekam Biotechnology AG was found in 1999. It started offering DNA-Tests in 2001. From 2004, it started development of PCR kits while exporting to 5 countries, today (2015) it exports to 70 countries in the world. Genekam covers different targets ...
based inMadison, WISCONSIN (USA)
Through a lot of hard work, a license from the Wisconsin Alumni Research Foundation (WARF) and a desire to have an impact on human health, NeoClone was founded in 1999 by three University of Wisconsin scientists who recognized the need for better ...
based inRehovot, ISRAEL
Biolojic Design is committed to curing patients by designing and developing a pipeline of revolutionary therapeutics. Biolojic’s platform generates antibodies that bind to predefined epitopes, thus allowing for the design of specific functions: ...
based in
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs, announced merger with AVROBIO, Inc. The combined company will ...
based inVictoria, BRITISH COLUMBIA (CANADA)
IPA (ImmunoPrecise Antibodies NASDAQ: IPA ) is a biotherapeutic research company that brings industry leading antibody discovery services and complex artificial intelligence technologies together - to lead its pharmaceutical partners into the era of ...
based inSeattle, WASHINGTON (USA)
window into the adaptive immune system the world hadn’t thought possible. Together, Harlan and his brother Chad, founded Adaptive to meet the worldwide demand for immunosequencing technology. Over the past decade, we have developed our proprietary ...
Neutralizing antibodies defend healthy cells by interfering with the biological function of an invading virus. These antibodies may be used therapeutically to treat someone currently fighting the ...
based inFlorham Park, NEW JERSEY (USA)
Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and ...
We are developing CYNK-101 as a combination treatment for multiple cancer indications. CYNK-101 is manufactured from a specific type of immune cell, NK cells, that we extract from postpartum placentas and then genetically engineer to increase cell ...
based inWroclaw, POLAND
Pure Biologics is a biopharmaceutical company focused on the biological drug and non-systemic therapies discovery and development. We operate in the areas of immuno-oncology, autoimmunology, and rare neurological diseases, conducting research based ...
based inJupiter, FLORIDA (USA)
Dyadic International, Inc. (NASDAQ: DYAI) is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and ...
We are building an active pipeline of products for human health by applying our proprietary and patented C1 technology to develop vaccines and antibodies for infectious and other diseases. Vaccine Development: The C1 platform is ready for full ...
based inGosselies, BELGIUM
SYnAbs was founded in 2015 as a Belgian spin-off of the Catholic University of Louvain (UCL), based on the work of Prof. Hervé Bazin, the inventor of the world's first rat myeloma cell line. SYnAbs' vision is to fill the gap on the marketplace for ...
Transmembrane proteins are probably the most complex and challenging antigens to target with monoclonal antibodies. Indeed, despite their strong presence in the animal kingdom and their implications in many cellular mechanisms, they remain very ...
based inBasel, SWITZERLAND
Granite Bio is at the forefront of biotechnological innovation, concentrating on the treatment of chronic inflammatory, autoimmune, and fibrotic diseases. These conditions are prevalent as they lack effective therapeutic options, resulting in ...
Novel Therapeutic Target: Proprietary patient profiling identified novel disease biology node in inflammation, autoimmunity and ...
based inCambridge, UNITED KINGDOM
Biosceptre is a biopharmaceutical company focused on chimeric antigen receptor (CAR) T-cell therapy and immune-oncology treatment, that’s committed to bringing a new range of targeted therapies to a wide range of cancer patients. With Nobel ...
We are also developing antibodies that specifically target nfP2X7 for use in both solid and haematological tumours. Our preclinical data is very promising and studies show an excellent safety profile. By exploiting the modular ...
based inCambridge, MASSACHUSETTS (USA)
We are a group of individuals who know that there is a better way to develop drugs. Our business model and broad, science-based portfolio has attracted some of the brightest minds in drug development. Our team brings together more than 300 years of ...
BOS-371 is a highly potent monoclonal antibody targeting the Interleukin-1 Receptor Accessory Protein (IL1RAP), a prevalent tumor associated antigen driving tumor growth and immunosuppression. BOS-371 has also been Fc-engineered to enhance effector ...
based inSeoul, SOUTH KOREA
Eutilex is Developing anti-tumor T cell therapy and antibody therapeutics based on its own proprietary immunotherapy technology We set a goal to be a leading company in anti-tumor immunotherapy markets through the technical innovation & early ...
Fully humanized anti-human 4-1BB monoclonal antibody. Agonistic effect of EU101 promotes cytotoxic T lymphocyte response and it leads to eradication of ...
based inYokohama, JAPAN
MabGenesis Inc. is a biopharmaceutical startup that uses 30+ years of antibody research to provide first-in-class and best-in-class therapeutic monoclonal antibody drugs for humans and animals. We have the world’s highest quality antibody libraries ...
based inRedmond, WASHINGTON (USA)
SystImmune Inc. is a biopharmaceutical company focused on the treatment of cancer through developing novel therapeutic bi-specific, and multi-specific antibodies, as well as antibody-drug conjugates (ADCs). Our objective is to create biologics that ...
Guidance and Navigation Control (GNC) molecules are multi-specific cell engager proteins. GNC in the oncology therapeutics class bind to cancer cells and to immune cells and stimulate the immune cell cancer killing activity. By design, each GNC ...
based inHayward, CALIFORNIA (USA)
Novodiax is dedicated to advancing tissue-based diagnostics and immunoassays through innovation. Our signature technology platform is a proprietary polymer-based detection system. Based on this technology we have developed a series of highly ...
Novodiax has developed a proprietary polymerized HRP (polyHRP) technology through intelligent structural designs and optimized polymerization. This new technology platform allows us to provide powerful tools and services for researchers who seek ...
based inMechelen, BELGIUM
Galapagos discovers, develops and commercializes small molecule medicines with novel modes of action. Our pipeline comprises discovery through to Phase 3 programs in inflammation, fibrosis, and other indications. Our first medicine is approved and ...
